tert-butyl 3-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)piperidine-1-carboxylate

Catalog No. :
ACFZAG403
CAS No. :
1219827-82-3
Molecular Formula :
C14H21N3O4
Molecular Weight :
295.34

IUPAC Name:tert-butyl 3-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)piperidine-1-carboxylate

tert-butyl 3-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 3-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)piperidine-1-carboxylate
IUPAC Nametert-butyl 3-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)piperidine-1-carboxylate
Molecular FormulaC14H21N3O4
Molecular Weight295.34
SMILESCC(C)(C)OC(=O)N1CCCC(OC2=NNC(=O)C=C2)C1
InChI KeyDMQJLXRGKKILBX-UHFFFAOYSA-N
Synonymtert-butyl 3-[(6-oxo-1,6-dihydropyridazin-3-yl)oxy]piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3-[(1,6-dihydro-6-oxo-3-pyridazinyl)oxy]-, 1,1-dimethylethyl ester
CAS No.1219827-82-3

Safety Data

Pictogram
PICTOGRAM
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACFZAG403 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCVEW612 route compound structure diagram
    ACCVEW61285275-45-2 In Stock
  2. Plus
  3. ACEHMF832 route compound structure diagram
    ACEHMF83219064-67-6 In Stock
  4. Then
  5. ACFZAG403 route product structure diagram
    ACFZAG4031219827-82-3
Inquiry

2. ACFZAG403 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCVEW612 route compound structure diagram
    ACCVEW61285275-45-2 In Stock
  2. Plus
  3. ACYMQN926 route compound structure diagram
    ACYMQN92651355-94-3 In Stock
  4. Then
  5. ACFZAG403 route product structure diagram
    ACFZAG4031219827-82-3
Inquiry

Comments (0)